Effect of Citalopram on prevention of migraine headaches: a randomized clinical trial

سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 531

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

AMSMED19_046

تاریخ نمایه سازی: 1 دی 1397

چکیده مقاله:

Background and Objective: Migraine is the third most prevalent disease and the seventh most debilitating disease in the world. Migraine sufferers often have a lower quality of life compared to the general population. Selective Serotonin Reuptake-Inhibitors (SSRIs) was recommended for prevention of migraine headaches. Considering the insufficiency of similar studies, the aim of this study was to investigate the effect of Citalopram on prevention of migraine headaches. Materials and Methods: This double-blind randomized clinical trial (IRCT20161103030680N9) was conducted on patients diagnosed with migraine headaches based on the guidelines of the International Headache Society. Patients with age of 18-45 who met inclusion criteria such as recurring headaches for at least 6 months and at least 3 episodes per month and each episode lasted a minimum of 30 minutes were enrolled. Other patients suffering from other forms of headaches, using any form of analgesic drugs, beta blockers, tricyclic antidepressants, anticonvulsants, Mono-amine Oxidase Inhibitors, NSAIDs or corticosteroids, patients with sensitivity to similar drugs and finally those without consent were excluded. Finally, 226 patients were allocated randomly in two control and intervention groups. The intervention group treated with Citalopram 30mg daily for two months and the control group given placebo the same amount as the treatment group. Neither the patients nor the doctor had any information regarding the status of the placebo or active agent of the drugs administered to the groups. All patients were evaluated for the frequency, duration and severity of pain in the beginning of study and at the end of 1 and 2 months. Visual analogue scale (VAS) and 6-point behavioral rating scale (BRS-6) were used for evaluation of the severity of pain. Statistical analysis was carried out by SPSS statistical software, version 20.0 using Chi square, Mann-Whitney, Wilcoxon and T-test. In all analytical procedures, P <0.05 has been considered statistically significant. Findings: The mean age in placebo and Citalopram group was 31.97±8.82 and 32.61±8.01 respectively. The difference between the two groups in terms of age and gender were not statistically significant (P=0.8 and P=0.6 respectively). Even though initially there was no statistically significant difference between the two groups regarding the severity, duration and frequency of migraine headaches (P=0.9, P=0.49 and P=0.77 respectively), this parameter had significantly decreased after the first and second month of treatment (P<0.0001 in all parameters). Conclusion: Citalopram as a SSRI, possibly through a serotonin-lowering mechanism, leading to less frequent, less severe and shorter migraine episodes. This medication appears to be useful as a preventative drug used to treat of migraine headaches, especially in individuals suffering from both migraine headaches and depression.

نویسندگان

Siamak Afshinmajd

Associate Professor, Neurophysiology Research Center, Shahed University, Tehran, Iran

Iman Ansari

Medical Students Research Committee, Shahed University, Tehran, Iran

Elnaz Babakhani

Young Researchers and Elite Club, Tehran Medical Branch, Islamic Azad University, Tehran, Iran.